Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution Read more
Yimutian Inc. Announces Plan to Implement Change in American Depositary Shares (ADS) to Ordinary Share Ratio Read more
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy Read more
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Read more
Atour Lifestyle Holdings Limited to Report First Quarter 2026 Financial Results on May 13, 2026 Read more
Allot to Present at the 21st Annual Needham Technology, Media & Consumer Conference on May 13, 2026 Read more